Biogen ANZ News and Activities

Biogen ANZ is owned by Biogen.

Biogen is one of the...

• Forbes Global 2000 (#845);
• Fortune 500 (#421);
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Biogen is a company listed under the stock ticker BIIB (US).

Biogen has a direct presence in 9 countries.

Biogen has 9 subsidiaries including Biogen ANZ, Biogen BeLux and Biogen Canada.

They are in:

• Biotechnology90%
• Medical Equipment10%

Acquisition, funding and merger involving Biogen.

• Biogen has announced the acquisition of RayThera  (posted on June 18 2026).
• Biogen has announced the acquisition of Apellis Pharmaceuticals  (posted on March 31 2026).
• Biogen has announced the acquisition of Alcyone Therapeutics  (posted on September 24 2025).

View the org chart displaying its 3 main executives

Most searched biographies at Biogen ANZ

• David Henderson, Managing Director
• Camilla Chan, Head of Legal and Compliance
• Tim Mcgettigan, Head of Finance

Popular executive movements at Biogen

• Michael Parini will join the company as Chief Legal Officer on Aug. 3, 2026  (posted on July 15 2026).
• Jessie Lee has joined the company as Head of Commercial Learning and Development  (posted on June 24 2026).
• Maria Freire, who was Director, is promoted to Chairman of the Board  (posted on February 13 2026).

Click here to view some more movements at Biogen

Create your alert
to follow the executive moves at Biogen ANZ.

Biogen has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).
• Attovia Therapeutics has filed its IPO. Its stock ticker will be ATTO. (posted on July 15 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Biogen ANZ

• EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022 | Biogen
• The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus | Biogen
• FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS | Biogen
• Biogen to Report Second Quarter 2022 Financial Results July 20, 2022 | Biogen
• The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway | Biogen
• Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform | Biogen
• European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) | Biogen
• New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen) | Biogen
• The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities | Biogen
• Biogen Withdrawal from the Jefferies Healthcare Conference | Biogen
• View more press releases Close

Social media about Biogen ANZ

• Biogen ANZ on Wikipedia, Google News & Yahoo Finance
• Biogen ANZ on LinkedIn, X (Twitter) & YouTube